TG Therapeutics Inc (TGTX)
Cash ratio
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash and cash equivalents | US$ in thousands | 179,894 | 195,822 | 82,910 | 75,477 | 92,933 | 150,902 | 97,009 | 61,469 | 102,304 | 109,860 | 147,073 | 185,676 | 298,887 | 326,512 | 401,707 | 471,514 | 553,439 | 254,154 | 260,512 | 52,051 |
Short-term investments | US$ in thousands | 131,106 | 145,219 | 134,342 | 134,308 | 124,575 | 78,257 | 47,896 | 78,241 | 59,374 | 66,082 | 48,636 | 47,525 | 15,876 | 30,338 | 41,752 | 52,334 | 51,987 | 46 | 15,058 | 26,284 |
Total current liabilities | US$ in thousands | 90,679 | 125,114 | 108,664 | 99,684 | 53,720 | 57,678 | 72,667 | 63,076 | 53,201 | 36,447 | 43,326 | 54,656 | 65,384 | 87,655 | 87,551 | 92,494 | 87,554 | 77,670 | 67,537 | 63,118 |
Cash ratio | 3.43 | 2.73 | 2.00 | 2.10 | 4.05 | 3.97 | 1.99 | 2.21 | 3.04 | 4.83 | 4.52 | 4.27 | 4.81 | 4.07 | 5.07 | 5.66 | 6.91 | 3.27 | 4.08 | 1.24 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($179,894K
+ $131,106K)
÷ $90,679K
= 3.43
The cash ratio of TG Therapeutics Inc provides insight into the company's ability to cover its short-term obligations with its available cash and cash equivalents. A higher cash ratio indicates a stronger liquidity position and financial health.
Examining the data provided, we observe fluctuations in TG Therapeutics Inc's cash ratio over the quarters from March 31, 2020, to December 31, 2024. The cash ratio ranged from a low of 1.24 on March 31, 2020, to a high of 6.91 on December 31, 2020, indicating significant variability in the company's ability to cover its short-term obligations solely with cash.
Throughout the following quarters, the cash ratio generally remained above 4, signaling an adequate level of liquidity for TG Therapeutics Inc's short-term needs. However, there were occasional decreases in the cash ratio, such as the decline to 2.10 on March 31, 2024, which may merit further investigation into potential changes in the company's cash position or working capital management.
Overall, the cash ratio data suggests that TG Therapeutics Inc has maintained a reasonable level of liquidity over the analyzed periods, with the potential need to monitor any significant fluctuations to ensure the company's ability to meet its short-term obligations efficiently.
Peer comparison
Dec 31, 2024